## AN INFODEMIC OF FALSEHOODS IS CIRCULATING ONLINE ABOUT GLP-1 WEIGHT LOSS DRUGS.

Despite the FDA's requirements against mass compounding of GLP-1s, we are concerned that the marketing of compounded and other non-legal weight loss products will continue, confusing and hiding facts from consumers and patients who are managing chronic diseases like obesity.

Underscoring the potential health consequences from dosing errors and exposure to the wrong ingredients from compounded GLP-1s:

the FDA has received
775+
adverse event reports<sup>1</sup>

1,500%
increase in calls since 2019 related to side effects and overdosing<sup>2</sup>

## THE NATIONAL CONSUMERS LEAGUE RECOMMENDS 9 WAYS TO PROTECT PATIENTS AND IMPROVE THE REGULATION OF GLP-1 DRUGS:

- 1. Make combating infodemics a national priority
- Increase coverage and affordability of FDA-approved GLP-1 weight loss drugs
- 3. Enforce existing drug advertising rules
- 4. Explore a new role for the Federal Trade Commission
- 5. Increase pharmacovigilance of online pharmacy websites
- 6. Intensify federal and state efforts to protect consumers from counterfeiters
- 7. Implement labeling rules for compounders
- 8. Require compounders to submit adverse reaction reports to the FDA
- Require compounders to disclose information on the composition and distribution of compounded drugs



## COMPOUNDED GLP-1S CAN POSE POTENTIAL PATIENT RISKS.



Compounded GLP-1s are not FDA-approved.



Compounded GLP-1s are not required to meet the high safety, efficacy, and good manufacturing process standards for drugs that have received FDA approval.



Compounded drugs are **inappropriate for mass production** outside of FDA shortages.

i US Food and Drug Administration. "FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss." https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss. Accessed May 8, 2025.

ii America's Poison Centers. "GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS." https://poisoncenters.org/track/GLP-1. Accessed May 8, 2025.